BD-Waters merger closes at $18.8bn, BD gets $4bn cash

Becton, Dickinson and Company (BDX) completed the spin-merge of its Biosciences & Diagnostic Solutions business with Waters Corporation (WAT) on Feb. 9, closing a transaction the companies first valued at $17.5 billion. In its completion statement, BD said the final value at closing was $18.8 billion and that it received $4 billion in cash, while BD shareholders kept 39.2 per cent of the combined company. Waters said the exchange ratio was 0.135 of a Waters share for each BD share outstanding.

The closing left BD with cash and a large continuing stake rather than a full exit from the business. Waters, for its part, absorbed the diagnostics and biosciences assets into a broader laboratory platform. That structure makes the deal read less like a straightforward sale and more like a reshaping of both companies.

Tom Polen, BD’s chairman, chief executive and president, said in the company release that the transaction “marks the final milestone of our BD 2025 strategy.”

Udit Batra, Waters’s chief executive, said in the company’s closing statement that the combination “marks a pivotal moment for Waters.”

Waters shareholders hold the balance of the combined company, while former BD holders entered through the share exchange, according to Waters. For investors, that means the transaction does not produce a clean break between seller and buyer. Both shareholder groups remain exposed to integration, demand in diagnostics end markets and any margin gains or misses from the enlarged business.

What investors will watch

The structure also shows how far the transaction moved between announcement and close. The companies initially pitched the tie-up at $17.5 billion, but BD put the closing valuation at $18.8 billion. BD prepared the unit for separation, then turned that work into $4 billion of cash and a retained equity stake instead of an outright sale.

That gives Waters immediate scale in testing and diagnostics markets that would have taken years to build on its own. It also gives BD a simpler portfolio without fully giving up exposure to the carved-out business. The numbers are easy to map: $4 billion in cash, a 39.2 per cent stake and an exchange ratio that shows exactly how BD investors rolled into the new company.

Before the close, MedTech Dive reported that the companies had set Feb. 9 as the target date for completion. The report described the transaction at the earlier $17.5 billion valuation, making BD’s final $18.8 billion figure the sharper measure of the deal’s size at closing.

The next test is operational rather than legal. Waters has to show that the larger company can grow without losing execution across the added businesses. BD, meanwhile, has to show how the $4 billion cash proceeds and its retained stake fit into capital allocation after the separation.

Those are the measures investors will use over the next few quarters. Once the deal mechanics fall away, attention shifts to whether the combined company can deliver cleaner growth and whether BD can show that the cash-and-equity structure was worth more than a plain sale.